On September 3, 2019 Kitov Pharma Ltd. ("Kitov") (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, reported that Isaac Israel, CEO, and Gil Efron, Deputy CEO and CFO, will participate in the H.C. Wainwright 21st Annual Healthcare Conference that is being held in New York on September 8-10, 2019 (Press release, Kitov Pharmaceuticals , SEP 3, 2019, View Source [SID1234539254]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Mr. Israel will provide an overview of Kitov’s business strategy and pipeline during the live presentation. They will also participate in one-on-one meetings with investors who are registered to attend the conference.

Details of presentation are as follows:

H.C. Wainwright Annual Healthcare Conference

Presentation Date: September 10, 2019

Presentation Time: 12:05 p.m. – 12:30 p.m. ET

Location: Lotte New York Palace Hotel, New York, USA

The updated Kitov corporate presentation will be made available on the "Investor Relations" section on the Kitov website at View Source